EXPLORING THE EFFECT OF CHRONIC INFLAMMATION ON RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN CANCER
Precision medicine has allowed for the development of monoclonal antibodies that unmask the anti-tumor immune response. These agents have provided some patients durable clinical benefit. However, PD-1 and PD-L1 inhibitor therapies are effective in a small group (10-20%) of non-small cell lung cancer...
Main Author: | El-Refai, Sherif M. |
---|---|
Format: | Others |
Published: |
UKnowledge
2018
|
Subjects: | |
Online Access: | https://uknowledge.uky.edu/pharmacy_etds/82 https://uknowledge.uky.edu/cgi/viewcontent.cgi?article=1086&context=pharmacy_etds |
Similar Items
-
Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
by: Charissa A. C. Jessurun, et al.
Published: (2017-09-01) -
Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
by: Ya Xu, et al.
Published: (2020-10-01) -
Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC
by: Jialin Qu, et al.
Published: (2020-07-01) -
Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
by: YU Lin, et al.
Published: (2021-08-01) -
Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
by: Zou W, et al.
Published: (2021-07-01)